BeOne Q1 2026: revenue $1.5B (+35%), BRUKINSA $1.1B (+38%), diluted EPS $1.96/$3.24

BeOne Medicines Ltd.

2026-Q1 EPS reported $0.15 revenue$1,513,438,000

Total global revenue $1.5B for Q1 2026, up 35% from prior year.
BRUKINSA global revenue $1.1B, up 38% YoY, maintains BTKi leadership.
GAAP diluted EPS $1.96 (vs $0.01); non-GAAP diluted EPS $3.24 (vs $1.22).
GAAP net income $227M (vs $1.3M); adjusted net income $375M (vs $136M).
Free cash flow $161M, turnaround from negative $12M in prior year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BeOne Medicines Ltd. reported the three months ended March 31, 2026 results: revenue Total revenue $1,513,438, net income GAAP net income $227,357, EPS GAAP diluted EPS per ADS $1.96.

Period: the three months ended March 31, 2026
Revenue: Total revenue $1,513,438
Net income: GAAP net income $227,357
EPS: GAAP diluted EPS per ADS $1.96
Result: reported results

Exact text from the filing

U.S. dollars and unaudited) Three Months Ended March 31, 2026 2025 % Change Net product revenues $ 1,487,329 $ 1,108,530 34 % Other revenue $ 26,109 $ 8,749 198 % Total revenue $ 1,513,438 $ 1,117,279 35 % GAAP income from operations $ 249,902 $ 11,102 2,151 % Adjusted income from operations* $ 414,394 $ 139,357 197 % GAAP net income $ 227,357 $ 1,270 17,802 %

View on SEC.gov

Browse all earnings releases →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001628280-26-030866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.